Invention Grant
US08017765B2 RNA interference mediated treatment of alzheimer's disease using short interfering nucleic acid (siNA)
有权
使用短干扰核酸(siNA)的RNA干扰介导的阿尔茨海默病的治疗
- Patent Title: RNA interference mediated treatment of alzheimer's disease using short interfering nucleic acid (siNA)
- Patent Title (中): 使用短干扰核酸(siNA)的RNA干扰介导的阿尔茨海默病的治疗
-
Application No.: US12640411Application Date: 2009-12-17
-
Publication No.: US08017765B2Publication Date: 2011-09-13
- Inventor: James McSwiggen , Leonid Beigelman
- Applicant: James McSwiggen , Leonid Beigelman
- Applicant Address: US NJ Rahway
- Assignee: Merck Sharp & Dohme Corp.
- Current Assignee: Merck Sharp & Dohme Corp.
- Current Assignee Address: US NJ Rahway
- Agent Laura M. Ginkel; David A. Muthard
- Main IPC: C07H21/04
- IPC: C07H21/04

Abstract:
The present invention concerns methods and reagents useful in modulating BACE gene expression in a variety of applications, including use in therapeutic, diagnostic, target validation, and genomic discovery applications. Specifically, the invention relates to small nucleic acid molecules, such as short interfering nucleic acid (siNA), short interfering RNA (siRNA), double-stranded RNA (dsRNA), micro-RNA (miRNA), and short hairpin RNA (shRNA) molecules capable of mediating RNA interference (RNAi) against beta-secretase (BACE), amyloid precursor protein (APP), pin-1, presenillin 1 (PS-1) and/or presenillin 2 (PS-2) gene expression and/or activity. The small nucleic acid molecules are useful in the treatment of Alzheimer's disease and any other condition that responds to modulation of BACE, APP, pin-1, PS-1 and/or PS-2 expression or activity.
Public/Granted literature
- US20100168208A1 RNA INTERFERENCE MEDIATED TREATMENT OF ALZHEIMER'S DISEASE USING SHORT INTERFERING NUCLEIC ACID (siNA) Public/Granted day:2010-07-01
Information query